Cerebral Palsy Market: The increasing prevalence of cerebral palsy is projected to boost market growth during the forecast period of 2022 to 2030

Pune, India, August 2018/MRFR Press Release/- Market Research Future has published a half-cooked research report on the global cerebral palsy market.

Market Highlights

Cerebral Palsy market is projected to USD 3.24 billion by 2030, at 3.20% CAGR during the forecast period 2023 - 2030.

Cerebral palsy (CP) is a congenital disorder that affects the muscle tone, movement, and motor skills. CP is generally considered to be caused by brain damage that happens before or during the baby's birth. The signs and symptoms of CP vary from person to person. According to the Centers for Disease Control and Prevention (CDC), some of the signs and symptoms of clinical palsy includes coordination and control problem, lack of muscle control, oral motor problems, and abnormal reflex responses. Currently, there are a wide variety of medications and therapies available to help people with cerebral palsy.

The increasing prevalence of cerebral palsy coupled with increasing awareness about the condition is anticipated to drive the global cerebral palsy market. According to an article published by the National Center for Biotechnology Information (NCBI) in 2017, the overall birth prevalence of cerebral palsy is approximately 2 per 1,000 births worldwide. Moreover, the rising adoptions of medications for controlling the symptoms of the cerebral palsy are expected to boost the market growth. In addition, rising healthcare expenditure in developed economies and increasing insurance coverage contributes to the growth of the market during the assessment period. On the other hand, side effects associated with medications and high treatment cost and lack of awareness in some developing regions may hinder the growth of the market.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Cerebral Palsy Market Research Report

Regional Analysis

The Americas is expected to dominate the global cerebral palsy market during the forecast period owing to the well-established healthcare sector, growing awareness about CP, and the rising prevalence of cerebral palsy in the region. The European market is expected to be the second-largest market due to the growing healthcare expenditure and increasing prevalence of cerebral palsy. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the forecast period owing to the developing healthcare infrastructure, and favorable government initiatives for the healthcare sector. The Middle East & Africa is likely to account for the least market share of the global cerebral palsy market owing to the lack of economic development, especially in the African region.

Segmentation

The global cerebral palsy market has been segmented into type, diagnosis, and treatment.

The market, on the basis of type, has been segmented into spastic cerebral palsy, dyskinetic cerebral palsy, hypotonic cerebral palsy, ataxic cerebral palsy, and mixed cerebral palsy.

The market, by diagnosis, has been segmented into imaging tests and others. The imaging tests have been further segmented into magnetic resonance imaging (MRI), cranial ultrasound, computed tomography, and electroencephalogram.

The market, by treatment, has been segmented into therapy, medication, surgery, and others. The therapy segment has been segmented into nutrition therapy, hyperbaric oxygen therapy, occupational therapy, physical therapy, stem cell therapy, and others. The medication segment has been segmented into anti-convulsant drugs, muscle relaxants, anti-depressant drugs, anti-inflammatory drugs, and others. Further, the surgery segment has been segmented into orthopedic surgery and others.

Global Cerebral Palsy Key Players

Some of the prominent players in the global cerebral palsy market are Allergen Plc, Cellular Biomedicine Group, Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline Plc, Abbott Laboratories, Acorda Therapeutics, Inc., Medtronic, Meridigen Biotech Co., Ltd., GW Pharmaceuticals Plc, and Cell Cure Neurosciences Ltd.